Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Livzon Pharmaceutical Group ( (HK:1513) ) just unveiled an announcement.
Livzon Pharmaceutical Group Inc. has received approval from the National Medical Products Administration to commence clinical trials for its new siRNA drug, YJH-012 injection, aimed at treating gout. This approval marks a significant advancement in their drug development efforts, potentially enhancing their market position by offering a novel treatment with long-lasting effects and improved safety.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$23.00 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. is a company operating in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company collaborates with other biotech firms to innovate in drug development, particularly in areas requiring advanced therapeutic solutions.
Average Trading Volume: 1,481,281
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$32.28B
See more data about 1513 stock on TipRanks’ Stock Analysis page.